Optimization of standard AML treatment: APL advances, adverse cytogenetics & post-remission therapy
Alan Burnett et al.
How to treat elderly CLL patients in the light of novel therapies
New salvage treatment for AML/MDS after allogeneic transplant: the VIOLA trial
BCR inhibitors improving CLL patient outcomes
The future of leukemia treatment in the elderly